This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Oct 1;28(28):4295-6.

doi: 10.1200/JCO.2010.30.4212. Epub 2010 Aug 9.

Harnessing innate immunity to suppress lymphoma

Freda K Stevenson, Peter W M Johnson

PMID: 20697076
DOI: 10.1200/JCO.2010.30.4212

Editorial

Harnessing innate immunity to suppress lymphoma

Freda K Stevenson et al. J Clin Oncol. 2010.

. 2010 Oct 1;28(28):4295-6.

doi: 10.1200/JCO.2010.30.4212. Epub 2010 Aug 9.

Authors

Freda K Stevenson, Peter W M Johnson

PMID: 20697076
DOI: 10.1200/JCO.2010.30.4212

No abstract available

PubMed Disclaimer

Comment on

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. Brody JD, et al. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697067 Free PMC article. Clinical Trial.

Similar articles

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. Brody JD, et al. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697067 Free PMC article. Clinical Trial.
Technology evaluation: CpG-7909, Coley.
Paul S. Paul S. Curr Opin Mol Ther. 2003 Oct;5(5):553-9. Curr Opin Mol Ther. 2003. PMID: 14601526 Clinical Trial.
Vaccines for lymphomas: idiotype vaccines and beyond.
Houot R, Levy R. Houot R, et al. Blood Rev. 2009 May;23(3):137-42. doi: 10.1016/j.blre.2008.09.001. Epub 2008 Oct 31. Blood Rev. 2009. PMID: 18951668 Review.
Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D. Verthelyi D. Methods Mol Med. 2006;127:139-58. doi: 10.1385/1-59745-168-1:139. Methods Mol Med. 2006. PMID: 16988453 Review.
A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. Conforti A, et al. Vaccine. 2010 Apr 30;28(20):3522-30. doi: 10.1016/j.vaccine.2010.03.020. Epub 2010 Mar 21. Vaccine. 2010. PMID: 20332048

See all similar articles

Cited by

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Smith DA, Conkling P, Richards DA, Nemunaitis JJ, Boyd TE, Mita AC, de La Bourdonnaye G, Wages D, Bexon AS. Smith DA, et al. Cancer Immunol Immunother. 2014 Aug;63(8):787-96. doi: 10.1007/s00262-014-1547-6. Epub 2014 Apr 27. Cancer Immunol Immunother. 2014. PMID: 24770667 Free PMC article. Clinical Trial.
An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.
Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. Zhang H, et al. PLoS One. 2012;7(5):e38111. doi: 10.1371/journal.pone.0038111. Epub 2012 May 30. PLoS One. 2012. PMID: 22666458 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information